William Blair Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
In a report released today, Matt Phipps from William Blair reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report). The ...
Prelude Therapeutics CEO buys $467K in common stock
In a regulatory filing, Prelude Therapeutics (PRLD) disclosed that its CEO Krishna Vaddi bought 675K shares of common stock on March 25th in a ...
DelveInsight Business Research, LLP: LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...